Table 2 Comparison between patients with and without acute kidney injury in the IMPELLA-PL and DRESDEN cohorts.

From: Prognostic impact of acute kidney injury on one-year survival in patients undergoing high-risk PCI with Impella support

Variable

IMPELLA-PL cohort

p-value

DRESDEN cohort

p-value

AKI

No AKI

AKI

No AKI

Baseline characteristics

Age [years]

73.6 ± 10.2

71 ± 9.5

0.18

78.6 ± 8.3

77 ± 9

0.32

Male sex

28 (84.8)

172 (87.8)

0.41

25 (75.8)

106 (70.7)

0.67

BMI [kg/m2]

27.3 ± 4.1

27.8 ± 4.7

0.5

28 ± 4.1

28 ± 5.5

0.92

Acute coronary syndrome

14 (46.7)

90 (46.9)

1.0

12 (36.4)

51 (34)

0.84

Hypertension

30 (90.9)

154 (78.6)

0.15

30 (90.9)

141 (94)

0.46

Atrial fibrillation

12 (36.4)

61 (31.1)

0.55

13 (39.4)

19 (12.7)

 < 0.001

Heart failure

28 (84.8)

155 (79.1)

0.64

33 (100)

149 (99.3)

1.0

NYHA class

3 [2]

3 [1]

0.13

3 [0]

3 [0]

0.62

Prior TIA

2 (6.1)

9 (4.6)

0.66

1 (3)

10 (6.7)

0.69

Prior stroke

2 (6.1)

18 (9.2)

0.75

5 (15.2)

22 (14.7)

1.0

Diabetes mellitus

13 (39.4)

94 (48)

0.45

19 (57.6)

67 (44.7)

0.25

COPD

3 (9.1)

24 (12.2)

0.78

4 (12.1)

10 (6.7)

0.29

Prior CABG

3 (9.1)

20 (10.2)

1.0

1 (3)

5 (3.3)

1.0

Prior ICD

9 (27.3)

31 (15.8)

0.14

3 (9.1)

3 (2)

0.73

CKD

20 (60.6)

77 (39.5)

 < 0.05

30 (90.9)

69 (46)

 < 0.001

EuroSCORE II

7 [6.4]

5 [6.5]

0.25

12 [6.8]

5 [1.9]

 < 0.001

SYNTAXSCORE

37 [24]

43 [22]

0.18

27 [18]

31 [13]

0.92

Mehran Risk score

13 [10]

10 [6]

 < 0.01

17 [4]

12 [4]

 < 0.01

Pre-procedural diagnostic results

Creatinine [mg/dL]

1.25 [0.93]

1.13 [0.49]

 < 0.05

1.45 [0.28]

1.06 [0.44]

 < 0.001

eGFR [ml/min/m2]

48 [28]

62 [36]

 < 0.01

45 [25]

69 [33]

 < 0.001

Hemboglobin [g/dL]

12.6 [2.8]

13 [2.5]

0.35

10 [1.6]

10.7 [2.6]

0.06

Hematocrit [%]

38.7 ± 5.1

39.7 ± 5

0.33

34.9 ± 5.5

36.7 ± 5.7

0.09

Red blood cells [10^6/uL]

4.4 [0.96]

4.3 [0.87]

0.88

3.13 [0.49]

3.83 [1.13]

 < 0.05

White blood cells [10^3/uL]

9.53 [4.66]

8.19 [3.67]

0.23

7.21 [0.87]

8.6 [3.15]

0.77

Platelet [10^3/uL]

209.5 [116]

208 [124]

0.71

317 [99]

268 [108]

0.59

NT-pro-BNP [pg/mL]

8820 [19749]

4092 [6555]

0.5

9182 [1463]

7250 [6165]

0.7

Troponin [ng/L]

136.5 [864]

234 [1064]

0.23

1036 [895]

441 [974]

 < 0.01

LVEDD [mm]

56.4 ± 7.5

60.54 ± 9.2

 < 0.05

52.4 ± 7.3

50.7 ± 8

0.29

LVEF [%]

31.3 ± 13.6

29.2 ± 12.7

0.46

40.4 ± 13.1

41.2 ± 14.7

0.78

LVEF < 35%

18 (69.2)

125 (73.1)

0.65

12 (36.4)

60 (41.4)

0.7

Moderate/severe MVR

6 (18.2)

33 (28.2)

0.78

11 (33)

44 (29.7)

0.68

Severe AVS

0 (0)

2 (1.2)

1.0

0 (0)

8 (5.5)

0.35

Number of vessels with significant stenosis

3 [1]

3 [1]

0.37

3 [2]

3 [0]

0.31

Chronic total occlusion

17 (51.5)

108 (55.1)

0.71

13 (39.4)

63 (42)

0.85

Procedural details and complications

Number of vessels treated with hrPCI

3 [2]

3 [1]

0.95

1 [0]

3 [1]

0.76

LM or equivalent treated with hrPCI

24 (72.7)

136 (69.4)

0.84

24 (72.7)

111 (74)

1.0

Total number of implanted stents

2 [1]

3 [2]

0.41

3 [1]

4 [3]

0.13

Contrast volume [mL]

215 [113]

250 [120]

0.25

200 [90]

150 [70]

 < 0.05

Duration of hrPCI [min]

150 [84]

145 [89]

0.32

109 [6]

118 [69]

0.27

Impella before hrPCI

22 (66.7)

167 (85.6)

 < 0.05

31 (93.9)

145 (98)

0.23

Impella 2.5

0 (0)

0 (0)

1.0

25 (75.8)

115 (76.7)

1.0

Catecholamines use during/after hrPCI

10 (30.3)

33 (16.8)

0.09

9 (27.3)

23 (15.3)

0.13

Renal replacement therapy after hrPCI

4 (12.1)

2 (1)

 < 0.01

0 (0)

0 (0)

1.0

Hemoglobin drop after hrPCI [10^6/uL]

1.4 ± 1.4

1.8 ± 1.6

0.22

1.9 ± 1

1.4 ± 1

 < 0.05

Red blood cells transfusion [units]

0 [0]

0 [0]

0.07

0 [0]

0 [0]

0.13

Bleeding from access site/limb ischemia

8 (24.2)

35 (17.9)

0.47

16 (48.5)

40 (26.8)

 < 0.05

  1. Values: mean ± standard deviation; number (%); median [interquartile range]. AKI, acute kidney injury; AVS, aortic valve stenosis; BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease (defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m2); COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; hrPCI, high-risk percutaneous coronary intervention; ICD, implantable cardioverter defibrillator; LM, left main; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MVR, mitral valve regurgitation; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TIA, transient ischemic attack.
Back to article page